Affiliation: Karolinska Institutet
- Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndromeMartin Jadersten
Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden
J Clin Oncol 26:3607-13. 2008..To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS)...
- Myelodysplastic syndromes: biology and treatmentM Jadersten
Division of Hematology and Center of Experimental Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
J Intern Med 265:307-28. 2009..We perform in depth analyses of two of the most widely used treatments, erythropoietin and lenalidomide, discussing mechanisms of action, reasons for treatment failure and influence on survival...
- Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progressionMartin Jadersten
Karolinska Institutet, Department of Medicine, Center for Experimental Hematology, Karolinska University Hospital, Stockholm, Sweden
Haematologica 94:1762-6. 2009....
- New clues to the molecular pathogenesis of myelodysplastic syndromesMartin Jadersten
Center for Experimental Hematology, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
Exp Cell Res 316:1390-6. 2010..An improved understanding of the pathophysiology of MDS may lead to the identification of suitable targets for future drug development...
- Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndromeM Carlsten
Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
Leukemia 24:1607-16. 2010..Thus, given the emerging evidence for NK cell-mediated immune surveillance of neoplastic cells, we speculate that reduced expression of DNAM-1 on bone marrow NK cells may facilitate disease progression in patients with MDS...